2 Cannabis Companies That Could Be the Next Industry Leaders

Canopy Growth has been the market leader since it was the first publicly traded cannabis company in Canada. It has continued to lead, earning some of the highest returns for investors and leading the charge to expand internationally.

There are, however, two companies that have not been far behind throughout the process. Now, as Canopy is stalling, there is an opportunity for them to catch up and possibly take over the position of market leader.

These companies have managed their finances well, have built up low-cost operations, and have made large export deals with international countries.

For long-term investors, two stocks that will be your best bet through the next phase of legalization are OrganiGram Holdings (TSX:OGI)(NASDAQ:OGI) and Aphria (TSX:APHA)(NYSE:APHA).

Organigram

OrganiGram is a Canadian cannabis producer headquartered in Moncton. It has been a top company from day one, even though it hasn’t gotten as much spotlight as some of its peers.

It’s one of only four companies to get sales agreements with all 10 provinces and is one of the only companies that has partnered up with celebrities, through its deal with the Trailer Park Boys.

It’s been increasing its production capacity, targeting a total capacity of 113,000 kg when it finishes Phase 4C of its expansion, which should be completed by the end of the year.

It has a unique three-level facility for cultivation that is located in Moncton. The three-level design has numerous advantages, but, most importantly, it maximizes OgraniGram’s footprint. It’s also using cutting-edge data to help drive decision making.

The company has many growth opportunities and has been focusing on the next phase of legalization using data based on U.S. information. This has led it to focus mainly on vape products and edibles, including beverages.

The company reported positive earnings before interest, taxes, depreciation, and amortization (EBITDA) in the third quarter. This was the fourth quarter in a row it had positive adjusted EBITDA. The adjusted EBITDA margin was an impressive 31%.

The company has a super low all-in cost of just $1.29 per gram, which allows it to be highly competitive. In addition, it has been managing its finances well and is financially sound. At the end of the third quarter, it had debt of less than $50 million against cash and short-term investments of nearly $90 million.

The company is trading for less than $1 billion, and the stock has tons of value below $6 a share.

Aphria

Aphria is one of the largest licensed producers in Canada with a market cap over $2 billion.

It’s been busy the last few years, building its numerous brands, expanding its production facility phases, and signing tons of deals all around the world.

On the recreational front, Aphria has agreements with all 10 provinces, as well as the Yukon. This gives it access to 99.8% of Canadians. On the medical side, it’s one of the only companies that has made a deal with Shoppers Drug Mart as well as continuing to do its direct-to-patient sales through e-commerce.

Its operations are truly global with partnerships in 10 countries and on five continents. The cannabis landscape continues to change globally, and Aphria is taking full advantage.

Furthermore, it has a huge runway for growth with its plans in Germany for the medical market. Germany is one of the best medical markets to get into due to its large customer base and insurance-sponsored medical cannabis program. This makes it one of the top international markets that companies are going for.

In the three months ended May 31, the company did over $125 million in sales with an adjusted gross margin of about 22%.

The stock is trading around $8.50, offering investors a huge discount while it stays under $10.

Bottom line

Both companies have huge growth opportunities, are low-cost producers, have good capital management, and are trading at rock-bottom prices. If you are looking for the next stock to lead the industry, you can’t go wrong with Aphria or OrganiGram.

You might be missing out on one of the biggest opportunities in Canadian investing history…

Marijuana was legalized across Canada on October 17th, and a little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

Besides making key partnerships with Facebook and Amazon, they’ve just made a game-changing deal with the Ontario government.

This is the company we think you should strongly consider having in your portfolio if you want to position yourself wisely for the coming marijuana boom.

Learn More About This TSX Stock Now

More reading

Fool contributor Daniel Da Costa has no position in any of the stocks mentioned.

Source: The Fool
2 Cannabis Companies That Could Be the Next Industry Leaders
The Fool

The Motley Fool
Contributor for investorsnews.ca
The Motley Fool is dedicated to helping the world invest — better. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, mutual funds, and premium investing services.

In all we do, we take a different approach.

We believe – and have proven over decades – that the individual investor can beat the market.

We believe that anyone can do it, even if they don’t have a lot of time or money to devote to investing.

We believe in a long-term outlook, helping people build wealth over time.

We believe that the person best positioned to take care of your financial future is you.

And we work tirelessly on behalf of our hundreds of thousands of members who are enjoying the opportunities that come with having enough money to do the things that matter to them.

While we are headquartered in Alexandria, Va., The Motley Fool advocates for the individual investor around the globe with offices in the UK, Australia, Canada, Singapore, and Germany.

Related posts